CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Experts are calling on the government to implement strategies that will better predict future Ozempic shortages.

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The Mayo Clinic said the supplement “may be safe when taken in recommended amounts” with the main side effects including ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Ozempic (semaglutide) is a brand-name drug prescribed to treat certain conditions, such as type 2 diabetes. Ozempic has interactions with some other drugs, such as insulin, and certain supplements.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.